Sunil Rajanikant Mehta
Directeur/Membre du Conseil chez Emcure Pharmaceuticals Ltd.
Fortune : 111 $ au 30/09/2021
Profil
Sunil Rajanikant Mehta is currently the Executive Director & Executive Director-Projects at Emcure Pharmaceuticals Ltd.
and Director at Gennova Biopharmaceuticals Ltd.
He completed his undergraduate degree from the University of Pune and his MBA from the Institute of Management, Development & Research.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
Emcure Pharmaceuticals Ltd.
 Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. 6,13% | 18/08/2021 | 11 085 012 ( 6,13% ) | 111 $ | 30/09/2021 |
Postes actifs de Sunil Rajanikant Mehta
| Sociétés | Poste | Début |
|---|---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Directeur/Membre du Conseil | 05/06/2013 |
Gennova Biopharmaceuticals Ltd.
 Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Gennova Biopharmaceuticals Ltd. specializes in biotechnology research for biosmiliars, vaccines, and mAbs using recombinant DNA technology. The company was founded on June 19, 2001 and is headquartered in Pune, India. | Directeur/Membre du Conseil | 19/06/2001 |
Formation de Sunil Rajanikant Mehta
| University of Pune | Undergraduate Degree |
| Institute of Management, Development & Research | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Health Technology |
Gennova Biopharmaceuticals Ltd.
Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Gennova Biopharmaceuticals Ltd. specializes in biotechnology research for biosmiliars, vaccines, and mAbs using recombinant DNA technology. The company was founded on June 19, 2001 and is headquartered in Pune, India. | Commercial Services |
